Aldosterone receptor antagonism (Inspra) in the first 24 hours of STEMI?

Benefit was shown in a trial presented at ACC but the composite endpoint was driven mainly by a surrogate marker (BNP/proBNP).   So....hypothesis generating and not ready for prime time pending further study.  Via Medpage Today.